Pain management during varicose vein treatment

Femoralblock in endovenous laser - FEMINE RCT

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-004347-37-FI

Enrollment

Registered

2016-11-22

Start date

2017-01-31

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

venous disease

Interventions

Trade Name: Lidocain c. adrenalin 5 mg/ml + 10 microg/ml Product Name: Lidocain c. adrenalin 5 mg/ml + 10 microg/ml Pharmaceutical Form: Injection Pharmaceutical form of the placebo: Injection Route o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 20 - 70 year old patients ( female and male) with great saphenous vein insufficiency Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 65 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 15

Exclusion criteria

Exclusion criteria: Arteriosclerosis, pregnancy, lymphoedema, severe obesity (BMI >40), neurological illness, severe co-morbidity, allergy to lidocaine

Design outcomes

Primary

Measure	Time frame
Main Objective: To improve pain management during varicose vein surgery;Secondary Objective: Not applicable;Primary end point(s): experienced pain during procedure, length of procedure, time spent in recovery room ;Timepoint(s) of evaluation of this end point: during procedure, exit from hospital	—

Secondary

Measure	Time frame
Secondary end point(s): return back to daily activities ;Timepoint(s) of evaluation of this end point: one month	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026